tirzepatide and prediabetes Comparison of Clinical Efficacy Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials | Advances in Therapy Tirzepatide, a New Era of

GLP-1 drugs , like most medical care, do not lower medical costs May 12, 2025 Summary: GLP-1 drugs do not lead to lower medical costs in the short run and are not likely to lead to lower medical costs even over a longer time horizon unless prices are substantially reduced

Yokote, K

Neuman T, Cubanski J

As easy as it may be to buy a best-selling blend or the one your gym buddy recommends, whats good for the goose isnt always good for the gander

Compared with other CVOTs involving GLP-1RA, participants in the AMPLITUDE-O trial had the longest duration of diabetes (15 years), lowest mean eGFR (72 ml/min/1.73 m 2 ) with a higher percentage (32%) of people with renal disease (eGFR 2560 mL/min), highest glycosilated hemoglobin (8.9%), and highest percentage of insulin use (62%) or sodiumglucose transporter-2 inhibitors (SGLT-2i) (15%) at baseline, thus identifying a more fragile population

DOI: 10.1016/S0140-6736(21)01324-6